Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Thoracic radiation therapy and Adriamycin/cisplatin-containing chemotherapy for locally advanced non-small-cell lung cancer

Eagan, R. T, M.D.a; Lee, R. E., M.D.b; Frytak, S., M.D.a; Scott, M., Ph.D.c; Ingle, J. N, M.D.a; Creagan, E. T., M.D.a; Nichols, W. C., M.D.a

American Journal of Clinical Oncology: January 1981 - Volume 4 - Issue 4 - p 381–388

ONEHUNDRED NINE PATIENTS with limited-stage unresonable non-small-cell lung cancer were treated with Adriamycin-cisplatin-based combination chemotherapy and thoracic irradiation. Of this number, 73 received chemotherapy (one course) prior to irradiation and 377 (27/73) had tumor regression following chemotherapy alone Sixty-eight percent of patients (73/107) experienced tumor regression following combined chemotherapy and irradiation. Ags more than 65 years, a maligant ipsilateral pleural effusion and no response to chenotherapy alone were all strong negative prognosticactors. Three-year survivals were as follows all 109 patients, 14.0% 89 patients without malignant pleural effusion, 17.0% 71 patients with neither a malignant pleural effusion nor malignant ipsilateral supraclavicular adenopathy, 23.1%.

a Division of Medical Oncology, Department of Oncology. May, Clinic, Rochester, Minnesota.

b Division of Therapeutic Radiology, Department of Oncology, Mayo Clinic, Rochester, Minnesota. c Department of Medical Research Statistics and Epidemiology, Mayo Clinic, Rochester, Minnesota.

© Lippincott-Raven Publishers.